Ionis Pharmaceuticals, Inc. Selling, General and Administrative Expense
Ionis Pharmaceuticals, Inc. (IONS) reported Selling, General and Administrative Expense of $150.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $150.40M, a 65.96% increase year-over-year.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $150.36M, a 97.19% increase year-over-year.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $130.19M, a 47.81% increase year-over-year.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $96.81M, a 57.06% increase year-over-year.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $393.87M, a 47.25% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $267.47M, a 14.98% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $232.62M, a 54.77% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $150.29M, a 19.35% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $150.40M 10-Q · filed 2026-07-29 | $300.75M 10-Q · filed 2026-07-29 | $430.94M derived: sum of 3 quarters · filed 2026-07-29 | $527.75M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $150.36M 10-Q · filed 2026-04-29 | $280.55M derived: sum of 2 quarters · filed 2026-04-29 | $377.35M derived: sum of 3 quarters · filed 2026-04-29 | $467.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $130.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $227.00M derived: sum of 2 quarters · filed 2026-02-26 | $317.62M derived: sum of 3 quarters · filed 2026-07-29 | $393.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | $96.81M 10-Q · filed 2025-10-29 | $187.43M derived: sum of 2 quarters · filed 2026-07-29 | $263.68M 10-Q · filed 2025-10-29 | $351.76M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $90.62M 10-Q · filed 2026-07-29 | $166.87M 10-Q · filed 2026-07-29 | $254.95M derived: sum of 3 quarters · filed 2026-07-29 | $316.59M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $76.25M 10-Q · filed 2026-04-29 | $164.33M derived: sum of 2 quarters · filed 2026-04-29 | $225.97M derived: sum of 3 quarters · filed 2026-04-29 | $291.08M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $88.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $149.72M derived: sum of 2 quarters · filed 2026-02-26 | $214.83M derived: sum of 3 quarters · filed 2026-02-26 | $267.47M 10-K · filed 2026-02-26 |
| 2024-09-30 | $61.64M 10-Q · filed 2025-10-29 | $126.75M derived: sum of 2 quarters · filed 2025-10-29 | $179.40M 10-Q · filed 2025-10-29 | $250.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $65.11M 10-Q · filed 2025-07-30 | $117.76M 10-Q · filed 2025-07-30 | $188.77M derived: sum of 3 quarters · filed 2026-02-26 | $258.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $52.64M 10-Q · filed 2025-04-30 | $123.66M derived: sum of 2 quarters · filed 2026-02-26 | $193.61M derived: sum of 3 quarters · filed 2026-02-26 | $239.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $71.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $140.96M derived: sum of 2 quarters · filed 2026-02-26 | $187.10M derived: sum of 3 quarters · filed 2026-02-26 | $232.62M 10-K · filed 2026-02-26 |
| 2023-09-30 | $69.95M 10-Q · filed 2024-11-06 | $116.09M derived: sum of 2 quarters · filed 2024-11-06 | $161.61M 10-Q · filed 2024-11-06 | $209.56M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $46.14M 10-Q · filed 2024-08-01 | $91.66M 10-Q · filed 2024-08-01 | $139.61M derived: sum of 3 quarters · filed 2025-02-19 | $174.02M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $45.52M 10-Q · filed 2024-05-07 | $93.47M derived: sum of 2 quarters · filed 2025-02-19 | $127.88M derived: sum of 3 quarters · filed 2025-02-19 | $161.68M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $47.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $82.37M derived: sum of 2 quarters · filed 2025-02-19 | $116.17M derived: sum of 3 quarters · filed 2025-02-19 | $150.29M 10-K · filed 2025-02-19 |
| 2022-09-30 | $34.42M 10-Q · filed 2023-11-02 | $68.22M derived: sum of 2 quarters · filed 2023-11-02 | $102.34M 10-Q · filed 2023-11-02 | $139.94M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $33.80M 10-Q · filed 2023-08-09 | $67.93M 10-Q · filed 2023-08-09 | $105.53M derived: sum of 3 quarters · filed 2024-02-21 | $136.62M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $34.13M 10-Q · filed 2023-05-03 | $71.73M derived: sum of 2 quarters · filed 2024-02-21 | $102.82M derived: sum of 3 quarters · filed 2024-02-21 | $159.28M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $37.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $68.69M derived: sum of 2 quarters · filed 2024-02-21 | $125.15M derived: sum of 3 quarters · filed 2024-02-21 | $186.35M 10-K · filed 2024-02-21 |
| 2021-09-30 | $31.09M 10-Q · filed 2022-11-09 | $87.55M derived: sum of 2 quarters · filed 2022-11-09 | $148.75M 10-Q · filed 2022-11-09 | $287.61M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $56.45M 10-Q · filed 2022-08-09 | $117.65M 10-Q · filed 2022-08-09 | $256.52M derived: sum of 3 quarters · filed 2023-02-22 | $324.97M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $61.20M 10-Q · filed 2022-05-04 | $200.07M derived: sum of 2 quarters · filed 2023-02-22 | $268.51M derived: sum of 3 quarters · filed 2023-02-22 | $340.53M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $138.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $207.31M derived: sum of 2 quarters · filed 2023-02-22 | $279.33M derived: sum of 3 quarters · filed 2023-02-22 | $354.32M 10-K · filed 2023-02-22 |
| 2020-09-30 | $68.45M 10-Q · filed 2021-11-03 | $140.46M derived: sum of 2 quarters · filed 2021-11-03 | $215.46M 10-Q · filed 2021-11-03 | $298.73M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $72.02M 10-Q · filed 2021-08-04 | $147.01M 10-Q · filed 2021-08-04 | $230.28M derived: sum of 3 quarters · filed 2022-02-25 | $290.32M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $74.99M 10-Q · filed 2021-05-05 | $158.27M derived: sum of 2 quarters · filed 2022-02-25 | $218.31M derived: sum of 3 quarters · filed 2022-02-25 | $293.42M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $83.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $143.31M derived: sum of 2 quarters · filed 2022-02-25 | $218.42M derived: sum of 3 quarters · filed 2022-02-25 | $286.64M 10-K · filed 2022-02-25 |
| 2019-09-30 | $60.04M 10-Q · filed 2020-11-04 | $135.15M derived: sum of 2 quarters · filed 2020-11-04 | $203.37M 10-Q · filed 2020-11-04 | $269.43M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $75.11M 10-Q · filed 2020-08-05 | $143.33M 10-Q · filed 2020-08-05 | $209.39M derived: sum of 3 quarters · filed 2021-02-24 | $278.10M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $68.22M 10-Q · filed 2020-05-06 | $134.28M derived: sum of 2 quarters · filed 2021-02-24 | $202.99M derived: sum of 3 quarters · filed 2021-02-24 | $269.19M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $66.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $134.77M derived: sum of 2 quarters · filed 2021-02-24 | $200.97M derived: sum of 3 quarters · filed 2021-02-24 | $244.62M 10-K · filed 2021-02-24 |
| 2018-09-30 | $68.71M 10-Q · filed 2019-11-06 | $134.91M derived: sum of 2 quarters · filed 2019-11-06 | $178.56M 10-Q · filed 2019-11-06 | $224.27M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $66.20M 10-Q · filed 2019-08-08 | $109.85M 10-Q · filed 2019-08-08 | $155.56M derived: sum of 3 quarters · filed 2020-03-02 | $182.34M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $43.65M 10-Q · filed 2019-05-09 | $89.36M derived: sum of 2 quarters · filed 2020-03-02 | $116.15M derived: sum of 3 quarters · filed 2020-03-02 | $138.46M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $45.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $72.49M derived: sum of 2 quarters · filed 2020-03-02 | $94.81M derived: sum of 3 quarters · filed 2020-03-02 | $108.49M 10-K · filed 2020-03-02 |
| 2017-09-30 | $26.79M 10-Q · filed 2018-11-06 | $49.10M derived: sum of 2 quarters · filed 2018-11-06 | $62.78M 10-Q · filed 2018-11-06 | $80.82M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $22.32M 10-Q · filed 2018-08-07 | $35.99M 10-Q · filed 2018-08-07 | $54.04M derived: sum of 3 quarters · filed 2019-03-01 | $64.22M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $13.68M 10-Q · filed 2018-05-07 | $31.72M derived: sum of 2 quarters · filed 2019-03-01 | $41.91M derived: sum of 3 quarters · filed 2019-03-01 | $51.73M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $18.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $28.23M derived: sum of 2 quarters · filed 2019-03-01 | $38.05M derived: sum of 3 quarters · filed 2019-03-01 | $48.62M 10-K · filed 2019-03-01 |
| 2016-09-30 | $10.19M 10-Q · filed 2017-11-07 | $20.01M derived: sum of 2 quarters · filed 2017-11-07 | $30.57M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $9.82M 10-Q · filed 2017-08-09 | $20.39M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $10.56M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $37.17M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |